top of page

Basel headquartered Nouscom is developing cancer vaccines with a platform that enables it to pack a high number of neoantigens into its product candidates

CEO Marina Udier describes how the company is developing an off the shelf product that includes over 200 neoantigens, a personalized product with 60 neoantigens, and is also developing a vaccine that is meant to prevent the occurrence of cancer in Lynch Syndrome carriers.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

SAV_Logo_2024.png

At Savills, the Life Sciences Team specializes in helping biotech companies unlock their full potential by aligning real estate strategies with their scientific and business goals. As a leading global commercial real estate advisory firm, we focus exclusively on occupier services and tenant representation, acting as a trusted partner to some of the most innovative companies in the industry.

bottom of page